Role of MTA1 in head and neck cancers

Abstract

Head and neck cancers usually originate in the squamous cells that line the inner mucosal surfaces of the oral and the neck region. These cancers follow multifocal steps for progression that include risk of developing metastasis. Although therapeutics has advanced in the past decades, head and neck cancers continue to cause much morbidity and mortality. Even with the promising effect of targeted therapies, there is a need for a better evaluation of patients with head and neck cancers. Metastasis-associated tumour antigen 1 (MTA1), a chromatin modifier, is found as an integral part of nucleosome remodelling and histone deacetylation (NuRD) complex. MTA1 is a biomarker for several solid tumours, and the overexpression of which have been documented in various cancers such as breast, ovarian, colon, prostrate etc. Interestingly also, a set of head and neck cancers shows MTA1 overexpression. However, recent evidences from clinical data raise a critical question on the role of MTA1 in head and neck cancers. This calls for a detailed review to the role of MTA1 in oral cancer. This review gives a brief account on the existing biological and molecular data in the context of head and neck cancer invasion and metastasis in relation to MTA1.

Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model

“…[65][66][67] Previous studies revealed that MTA1 is one of the most upregulated proteins in human cancer, and it is associated with cancer progression, aggressive phenotypes, and poor prognosis in patients with cancer. 26,67 In the present study, both DcR3 and MTA1 were overexpressed in OSCC patients (Figures 2 and 5), and MTA1 was positive correlated with DcR3 expression in the clinical data ( Figure 5A). Interestingly, TPL repressed both DcR3 and MTA1 expression in vitro, in vivo, and in the PDTX model of OSCC (Figures 3-5).…”

“…Overexpression of MTA1 is associated with the progression of various cancer types, including those of the head and neck. 25,26 These results suggest that the correlation between DcR3 and MTA1 might contribute to cancer progression in patients with OSCC.…”

“…MTA1 is a component of several chromatin remodeling complexes, including the nucleosome remodeling and deacetylation complex . Previous studies revealed that MTA1 is one of the most upregulated proteins in human cancer, and it is associated with cancer progression, aggressive phenotypes, and poor prognosis in patients with cancer . In the present study, both DcR3 and MTA1 were overexpressed in OSCC patients (Figures and ), and MTA1 was positive correlated with DcR3 expression in the clinical data (Figure A).…”

“…Notably, studies that have applied data mining to analyze DcR3 promoter using bioinformatic tools on the GENECARD web site (http://www.genecard.com) have revealed that MTA1 is a transcription factor of DcR3. Overexpression of MTA1 is associated with the progression of various cancer types, including those of the head and neck . These results suggest that the correlation between DcR3 and MTA1 might contribute to cancer progression in patients with OSCC.…”

MTA1 promotes viability and motility in nasopharyngeal carcinoma by modulating IQGAP1 expression

“…Metastasis‐associated protein 1 (MTA1), with MTA2 and MTA3, belongs to a family of chromatin modifier . MTA1 plays a major part in the nucleosome remodeling and histone deacetylation (NuRD) complex, which has the capability of transcriptional regulation and chromatin remodeling . Collective evidence has demonstrated the role of MTA1 in tumor cell metastasis and progression.…”